OXFORD University Innovation, the research commercialisation company of Oxford University, is launching a new biotech spinout, Oxford Antibiotics.
The company plans to develop a new drug in the multi-billion-pound antibiotic market, targeting MRSA, infectious endocarditis, SSSI, and healthcare-associated pneumonia.
It is looking to secure £3m in seed funding.
The move is part of the university’s drive to tackle antibiotic resistance, which claims 700,000 lives a year.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here